Myriad Genetics Inc
XMUN:MYD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Myriad Genetics Inc
XMUN:MYD
|
US |
|
Honda Motor Co Ltd
TSE:7267
|
JP |
|
M
|
Myriad Genetics Inc
XHAM:MYD
|
US |
|
C
|
China Vast Industrial Urban Development Company Ltd
HKEX:6166
|
HK |
|
B
|
Buckle Inc
SWB:BK2
|
US |
|
Kumba Iron Ore Ltd
OTC:KIROY
|
ZA |
|
Forvia SE
PAR:FRVIA
|
FR |
|
M
|
Manhattan Associates Inc
F:MHT
|
US |
Myriad Genetics Inc
Myriad Genetics makes genetic tests that help doctors understand a patient’s risk for certain diseases and choose treatment more precisely. Its core products are laboratory tests in areas such as hereditary cancer, women’s health, and some pharmacogenomic tests that look at how a person may respond to a medicine. The company sells these tests through physicians, hospitals, and health systems, and it gets paid when the tests are ordered and processed. The business is built around turning DNA analysis into a clinical service. Patients do not buy a box or a device; instead, their samples are sent to Myriad’s labs, where the company runs the test and returns an interpreted report to the doctor. That makes Myriad more of a specialty diagnostics provider than a traditional medical product company. Myriad also works with drug makers on companion diagnostics and research programs that link a therapy to the right patient group. In that part of the business, it helps biopharma companies develop and validate genetic tests that support drug use. This mix of direct clinical testing and partner work gives Myriad a role at the point where genetics, diagnosis, and treatment decisions meet.
Myriad Genetics makes genetic tests that help doctors understand a patient’s risk for certain diseases and choose treatment more precisely. Its core products are laboratory tests in areas such as hereditary cancer, women’s health, and some pharmacogenomic tests that look at how a person may respond to a medicine. The company sells these tests through physicians, hospitals, and health systems, and it gets paid when the tests are ordered and processed.
The business is built around turning DNA analysis into a clinical service. Patients do not buy a box or a device; instead, their samples are sent to Myriad’s labs, where the company runs the test and returns an interpreted report to the doctor. That makes Myriad more of a specialty diagnostics provider than a traditional medical product company.
Myriad also works with drug makers on companion diagnostics and research programs that link a therapy to the right patient group. In that part of the business, it helps biopharma companies develop and validate genetic tests that support drug use. This mix of direct clinical testing and partner work gives Myriad a role at the point where genetics, diagnosis, and treatment decisions meet.
Revenue: Myriad reported first-quarter revenue of $200.4 million, in line with guidance and up 2% year over year, with management reaffirming full-year 2026 guidance.
Hereditary cancer: Cancer Care Continuum revenue was $120.2 million, up 4%, and hereditary cancer test volume grew 14%, with especially strong growth in the unaffected population.
GeneSight: Mental health remained a bright spot, with GeneSight revenue of $38.3 million, up 24% year over year on 7% volume growth, helped by better reimbursement and payer coverage.
Prenatal: Prenatal revenue fell 15% year over year to $41.9 million, but management said the business is stabilizing and still expects a return to growth in the second half of 2026.
New products: Precise MRD launched in a limited breast-cancer alpha phase in March, Prolaris+AI is slated to launch in June, and FirstGene remains on track for a second-half commercial launch.
Profitability: Gross margin held at 68.7%, adjusted EBITDA was a loss of about $5 million, and management said higher launch-related spending is being balanced against a commitment to profitable growth.
